332 results about "Inflammatory cell" patented technology

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention discloses an application of core proteoglycan or a coding gene thereof as a target spot in preparation of psoriasis treatment drugs, and a series of experiments prove that DCN can effectively protect mouse psoriasis-like dermatitis induced by imiquimod, improve skin scale, erythema, thickening and epidermal abnormal differentiation, enhance the barrier function of skin, improve the curative effect of psoriasis, and improve the curative effect of psoriasis. A large amount of infiltration of inflammatory cells is reduced, and a certain anti-inflammatory effect is achieved. Experimental research shows that the DCN has an obvious drug effect on a psoriasis model, is safe and efficient, has no side effect, is simple in production process and has the potential of realizing medical transformation. And the potential application value of the DCN on other various skin inflammatory diseases can be expanded.

The invention discloses a grape seed source anti-inflammatory peptide, and belongs to the technical field of biological medicine. The amino acid sequence of the anti-inflammatory peptide is selected from any one of WGF, SHFGF, EGPFF, WAPR, SFYRAF, HFAFL, PGRF or FDSF. A BPS-induced RAW 264.7 mouse mononuclear macrophage inflammation model is established, and the eight synthetic peptides are found to significantly reduce the content level of NO in inflammatory cells and have an inhibition effect on secretion of inflammatory factors TNF-alpha and IL-6. A qRT-PCR (quantitative reverse transcription-polymerase chain reaction) experiment shows that the synthetic peptide can inhibit expression of mRNA (messenger Ribonucleic Acid) of p65, Tnf alpha, Il6, Il1b and Nos2, and can play an anti-inflammatory role by regulating and controlling an NF-kappa B signal channel. According to the method, the high-activity anti-inflammatory peptide is screened from the wine brewing byproduct grape seeds for the first time, and green and high-value utilization of the grape processing byproduct is realized.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

A composition for the surface treatment of a polymer material includes a hyperbranched polyglycerol comprising a glycidol-derived repeating unit and an unsubstituted or substituted acrylate group at least at one end thereof. The composition has the effect of suppressing fibrosis, thrombus formation, or inflammatory cell adsorption by preventing proteins from being adsorbed to the surface of a polymer material that is surface-treated with the composition or an in-vivo implantation material including a polymer material.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses a quantitative index determination method and device based on a hepatitis pathology image, equipment, a medium and a product, and relates to the field of medical pathology image artificial intelligence analysis, and the method comprises the steps: obtaining an image of a liver puncture pathology section; according to the image of the hepatic puncture pathological section, performing feature extraction by using a multi-stage model cascade architecture to obtain a pathological feature result; the multi-stage model cascade architecture comprises an improved VM-UNet segmentation model and a VM classification model based on FEM enhancement, and the VM classification model is connected with the improved VM-UNet segmentation model; the pathological feature result comprises the expansion level of the manifold area, the necrosis type of the manifold area and the inflammatory cell information of the manifold area; and calculating a quantitative index according to the pathological feature result. According to the invention, the accuracy, objectivity, consistency and repeatability of identification can be improved.

The invention discloses probiotics with an effect of improving vaginitis and a composite microecological preparation and application of the probiotics. The probiotics are characterized by comprising at least one of a plant lactobacillus 22-9 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.33867, a plant lactobacillus XA-9 strain with the preservation number of CGMCC No.33868 and a plant lactobacillus pentosus B-1-35 strain with the preservation number of CGMCC No.33870, the preparation method comprises the following steps: inoculating a lactic acid bacteria starter, which is prepared by mixing lactic acid bacteria cultures of plant lactobacillus 22-9, plant lactobacillus XA-9 and plant lactobacillus pentosus B-1-35 according to a volume ratio of 2: 1: 3, into a fermentation culture medium according to a volume ratio of 1-5%, so as to prepare the probiotic compound microecological preparation. The number of inflammatory cells in the vagina is reduced, and the levels of inflammatory factors IL-1beta, IL-6 and TNF-alpha in serum are reduced.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The invention discloses an application of a training immune agonist in preparation of a drug for sensitizing radiotherapy treatment of tumors, and researches show that the training immune agonist significantly activates immune response of a body by promoting expression of inflammatory cytokines, enhancing phagocytic ability of macrophages, recruiting immune cells and amplifying an immune activation effect, so that the immune response of the body is enhanced. The sensitivity of tumor cells to radiotherapy is improved, and a dual mechanism of'radiotherapy sensitization-immune synergy 'is formed, so that the bottleneck of the traditional radiotherapy curative effect is broken through, the local control rate of radiotherapy is improved, and the recurrence risk is reduced. Experiments prove that the training immune agonist combined with radiotherapy has a remarkable treatment effect on various highly invasive tumors (such as brain glioma and lung cancer brain metastasis) and common malignant tumors (such as colon cancer and lung cancer), and shows wide applicability. The invention provides a new combined therapy direction for tumor treatment, is expected to improve the prognosis of patients, prolong the lifetime and improve the life quality, and has important clinical transformation value.

The invention belongs to the technical field of medicines, and particularly relates to application of hordenine in preparation of a medicine for treating and relieving tissue damage. It is found that hordenine shows the effect of relieving immunological liver injury and spleen injury on an animal model, therefore, the application of hordenine to preparation of the medicine for treating and relieving tissue injury is provided, hordenine shows a remarkable curative effect, symptoms of immunological liver injury and pathological injury of spleen and thymus can be effectively relieved, and the hordenine can be used for preparing the medicine for treating and relieving tissue injury. The conditions include abnormal liver cell morphology, inflammatory cell tissue infiltration, pathological injuries such as extravasated blood and necrosis, cell apoptosis and the like. Animal experiments show that no obvious toxic reaction or side effect is observed while the hordenine is used for relieving immunological liver injury, spleen injury and thymus injury.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The invention relates to application of roxburgh rose-derived exosomes (RrNVs) in preparation of products for preventing, improving or treating acute lung injury (ALI). Specifically, the rosa roxburghii tratt exosome (RrNVs) can effectively inhibit inflammation, improve the acute lung injury symptom, reduce the release of inflammatory cells and inflammatory mediators in the acute lung injury state, and relieve the pulmonary edema condition, the lung tissue leakage condition and the lung capillary permeability condition in the inflammatory state. Meanwhile, the RrNVs can also regulate and control the intestinal flora structure, improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, and the discovery provides a basis for the RrNVs as potential functional food, medicine and the like of ALI.

The invention discloses an application of a pyroptosis inhibitor in preparation of a product for treating biliary atresia, the pyroptosis inhibitor 2-bromohexadecanoic acid has a certain treatment effect on biliary atresia mice, can significantly prolong the survival time of the mice, improve jaundice, improve the liver function of the mice, reduce the infiltration quantity of inflammatory cells around intrahepatic bile ducts, and can be used for treating the biliary atresia. A new potential target and a treatment strategy are provided for treatment of biliary atresia.

The invention belongs to the technical field of biological medicines, and particularly relates to application of small interfering RNA (Ribonucleic Acid) of a targeted Zyx gene. The invention provides siRNA (small interfering Ribonucleic Acid) of a targeted Zyx gene, and further provides application of the siRNA in prevention and treatment of fibrosis interstitial lung diseases. Experimental data prove that in a mouse bleomycin model, siRNA of a targeted Zyx gene can effectively improve the survival rate of a sick mouse, alveolar wall thickening, lung substantive thickening and inflammatory cell infiltration of a Zyx knock-down group are not obvious, and pathological damage caused by bleomycin is effectively relieved through knock-down of the Zyx gene; collagen fiber deposition of a Zyx knock-down group is reduced, and the transcription level of fibrosis-related genes is obviously reduced.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine compound for reducing recurrence of chronic nasosinusitis and a preparation method of the traditional Chinese medicine compound, and the traditional Chinese medicine compound is prepared from, by weight, 14-16 g of radix astragali, 8-10 g of fried radix scutellariae, 8-10 g of radix angelicae, 5-7 g of fructus xanthii, 5-7 g of flos magnoliae, 14-16 g of flos chrysanthemi indici, 11-13 g of fried fructus gardeniae, 5-7 g of radix angelicae sinensis, 5-7 g of flos carthami and 8-10 g of herba menthae. The traditional Chinese medicine composition can significantly improve clinical symptoms of patients with chronic nasosinusitis and reduce the recurrence rate, is good in safety, and does not find abnormal symptoms in clinical use. Meanwhile, the preparation process is simple to operate and suitable for industrial mass production. The raw medicinal materials selected by the traditional Chinese medicine composition are synergistic and complementary in nature and effect, inherit the holism concept of traditional Chinese medicine, emphasize that the traditional Chinese medicine composition emphasizes whole body treatment, plays a role together and inhibits infiltration of inflammatory cells while treating local parts, has small toxic and side effects, fully plays the advantages of treating chronic sinusitis and preventing relapse of the traditional Chinese medicine, relieves the pain of patients, and has a remarkable curative effect on treating chronic sinusitis. The life quality of patients is improved and the recurrence probability is reduced.

The invention relates to the technical field of hyaluronic acid derivatives and nano drug delivery systems, in particular to a lipoic acid grafted hyaluronic acid derivative, a preparation method and application, and provides a lipoic acid grafted hyaluronic acid derivative with a structure that lipoic acid is grafted with hyaluronic acid through a thioketal bond. A lipoic acid grafted hyaluronic acid derivative loaded IAA drug delivery system is constructed, can be gathered at a colitis disease part through intravenous injection, and is actively absorbed by cells by virtue of the affinity effect of hyaluronic acid in a lipoic acid grafted hyaluronic acid derivative structure on CD44 receptors on the surfaces of inflammatory cells; according to the present invention, with the application of the IAA in the cell, the responsive structure degradation occurs in the intracellular high oxidative stress environment, and the IAA is delivered into the cell in the positioning manner, such that the IAA inhibits the inflammation generation by activating the AhR and the downstream oxidative stress and inflammatory reaction related pathway so as to promote the mucous membrane repair, and the problem that the colitis treatment drug cannot accurately act on the focus in the prior art is solved.

Disclosed is a new pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and / or the gastro-intestinal tract.

The present: invention relates to a pharmaceutical composition comprising curcumin and ginsenoside, and a formulation comprising same. Using curcumin and ginsenoids according to the present invention in combination with butyric acid and sucralfate restores cell growth, mobility, and endothelial cell tube-forming by ability reduced irradiation, and inhibits an inflammatory response induced in macrophages by LPS treatment. In addition, it was confirmed that, when an irradiated mouse is topically treated with the formulation according to the present invention comprising the compounds, intestinal epithelial tissue damaged by irradiation is restored and the expression of inflammatory cytokines in the intestinal tissue is suppressed. Furthermore, a mixture of a ginseng extract and a turmeric extract also restored the intestinal epithelial tissue damaged by irradiation. Therefore, the pharmaceutical composition comprising curcumin, ginsenoid, butyric acid, and sucralfate, or the pharmaceutical composition comprising a mixture of a ginseng extract and a turmeric extract, and the formulation according to the present invention comprising same can be utilized for treating radiation proctitis.

A method to obtain more effective CAR-T cells, which are FOXO1 inhibited. The inhibition of FOXO1 potentiates the ability to induce lysis of a target cell thanks to the increased expression of TNF-α and other inflammatory cytokines, induces spontaneous cell polarization comparable to that obtained by stimulation with chemokines and thus improves the motility of the cells, induces a sharp increase of memory T cells and allows to obtain more efficient CAR-T cells to treat solid tumors than classical CAR-T cells obtained with the known protocol. An 10 ex vivo method to obtain improved CAR-T cells including the steps of (i) cultivate T cells obtained from a subject with a FOXO1 inhibitor during a time of 2 to 10 days; (ii) transducing (or transforming) the T cells into CAR-T cells thanks to a known method.

The present invention discloses the application of burdock root polysaccharide in the preparation of a medicament for treating pulmonary hypertension, belonging to the field of pharmaceutical technology. The present invention prepares a medicament for treating pulmonary hypertension with burdock root polysaccharide as the sole active ingredient. The medicament comprises an effective amount of burdock root polysaccharide and pharmaceutically acceptable excipients. Experimental results show that burdock root polysaccharide significantly reduces the increase in pulmonary artery pressure induced by monocrotaline in rats, significantly inhibits the increase in right ventricular hypertrophy index, significantly alleviates pulmonary artery endothelial injury, medial thickening, excessive proliferation of medial cells and infiltration of inflammatory cells in rats with pulmonary hypertension, significantly alleviates the degree of pulmonary artery vascular muscleization in rats with pulmonary hypertension, has the effects of reducing pulmonary artery vascular remodeling and lowering pulmonary artery pressure, and has a significant therapeutic effect on pulmonary hypertension and right ventricular hypertrophy in rats, and can be applied to the preparation of a medicament for treating pulmonary hypertension.

A skin care composition includes a plurality of agents that include at least one retinol derivative that may comprise, for example, hydroxypinacolone retinoate, and at least one bark extract that may comprise, for example, Eperua falcata bark extract, the plurality of agents providing reduced retinol associated inflammation as compared with a composition that includes the at least one retinol and lacks the at least one bark extract. The plurality of agents may also include hydroxy acid, for example, comprising lactic acid. The composition may confer one or a combination of increased skin cell proliferation, improved cellular migration, improved cellular differentiation, an anti-inflammatory retinol genetic signature as demonstrated by via bulk-RNA sequencing of human keratinocytes and restores epidermal disruption and reduce IL-1A and IL-23 inflammatory cytokines in human ex-vivo skin models of chronic inflammation.

The invention discloses application of peimisine in preparation of an anti-fibrosis medicine, and belongs to the technical field of biological medicines. According to the application, mouse pulmonary interstitial fibrosis is induced through bleomycin, the treatment effect of peimine on pulmonary fibrosis is observed, and the influence of peimine on the pulmonary fibrosis process is explored. Results show that peimisine can reduce mouse lung index increase caused by bleomycin, improve damage of pulmonary alveolar structures of mice with pulmonary fibrosis, reduce aggregation of inflammatory cells, reduce serum fibrosis factors TGF-beta1 and inflammatory factors IL-2 of the mice with pulmonary fibrosis, and reduce the number of macrophages and neutrophils in BALF of the mice with pulmonary fibrosis. The peimisine has an obvious regulating effect on MRC-5 cell abnormal proliferation induced by TGF-beta1, can improve in-vivo pulmonary fibrosis induced by bleomycin by regulating the process of extracellular matrix and intercellular matrix, has an obvious treatment effect on mouse pulmonary fibrosis induced by bleomycin, is beneficial to development and utilization of peimisine, and has a good application prospect. And an effective method is provided for clinical treatment of pulmonary fibrosis.

The invention discloses a reverse-age anti-aging traditional Chinese medicine compound composition containing 2-oxoglutaric acid and a preparation method of the reverse-age anti-aging traditional Chinese medicine compound composition. The composition comprises ganoderma lucidum peptide, astragalus peptide, ginseng peptide, 2-oxoglutaric acid, gamma-aminobutyric acid, rehmannia, cistanche, Chinese yam, rhizoma polygonati, honeysuckle, dendrobium officinale and turmeric. The ganoderma lucidum peptide, the astragalus peptide, the ginseng peptide and other components cooperate with one another, so that free radicals can be removed, oxidation reaction can be inhibited, cell membranes can be stabilized, cell oxidative damage can be reduced, and senescence can be delayed. Components such as honeysuckle and turmeric can inhibit inflammation signal channels and reduce inflammatory factors, dendrobium officinale can regulate inflammatory cells, and astragalus membranaceus peptide and ginseng peptide can enhance immunity and reduce inflammatory hazards. In the cellular level, 2-oxoglutaric acid is used for supplying energy and regulating genes, and gamma-aminobutyric acid is used for improving sleep and promoting repair; on the whole, the multiple components can tonify vital qi, nourish viscera, improve qi and blood and improve skin and mental states. Through cooperation of multiple aspects, the disease risk is reduced.

Provided is a use of a Galectin-1 inhibitor in preparation of a drug for treating pulmonary fibrosis. Taking silicosis model mice as a subject, administration of a Galectin-1 inhibitor OTX008 to silicosis mice can effectively alleviate the progression of pulmonary fibrosis. Studies have shown that the lung function of mice with silicosis is improved significantly; transcription levels of inflammatory factors Il-1β and Il-6 in the lung tissue of silicosis mice are decreased, concentrations of IL-1β and IL-6 in the alveolar lavage fluid are also decreased, and the infiltration of inflammatory cells is decreased. In the lung tissue of silicosis mice, the transcription levels of fibrosis factors Col-I and Fn-1 are decreased, the collagen-specific amino acid hydroxyproline is decreased, the fibrosis lesions are decreased, and the degree of lesions is alleviated. Therefore, the Galectin-1 inhibitor can be used as a new treatment strategy for pulmonary fibrosis.